secwatch.observer — SEC 8-K summary
======================================

Issuer:     LIGAND PHARMACEUTICALS INC (LGND)
CIK:        0000886163
Form:       8-K
Filed at:   2024-08-06T23:59:59+00:00
Accession:  0000886163-24-000067
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ligand Q2 revenue rises 57% to $41.5M; GAAP net loss $51.9M on $33.8M Primrose Bio writedown
--------------------------------------------------------------------------------

- Total revenue $41.5M (+57% YoY); royalties $23.2M (+11%); Captisol $7.5M (+44%).
- GAAP net loss from continuing ops $51.9M ($2.88/sh) vs income $2.3M ($0.13) YoY; adjusted net income $25.8M ($1.40).
- Core adjusted net income $25.8M vs $11.7M YoY, excluding Viking stock sales and non-cash impairments.
- 2024 guidance reaffirmed: royalties $100-105M, total revenue $140-157M, core adj. EPS $5.00-$5.50.
- Completed $100M APEIRON Biologics acquisition (July 8); credit facility expanded to $125M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/886163/000088616324000067/0000886163-24-000067-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/886163/000088616324000067/lgnd-20240806.htm
  HTML page:      https://secwatch.observer/filing/0000886163-24-000067

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer